Nothing Special   »   [go: up one dir, main page]

DK0483194T3 - IgG3-antistoffer med forkortet hængselsregion og en komplementaktiveringstest - Google Patents

IgG3-antistoffer med forkortet hængselsregion og en komplementaktiveringstest

Info

Publication number
DK0483194T3
DK0483194T3 DK90910699.9T DK90910699T DK0483194T3 DK 0483194 T3 DK0483194 T3 DK 0483194T3 DK 90910699 T DK90910699 T DK 90910699T DK 0483194 T3 DK0483194 T3 DK 0483194T3
Authority
DK
Denmark
Prior art keywords
pct
complement activation
antibody
hinge region
complement
Prior art date
Application number
DK90910699.9T
Other languages
English (en)
Inventor
Terje Michaelsen
Inger Sandlie
Original Assignee
Dynal As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynal As filed Critical Dynal As
Application granted granted Critical
Publication of DK0483194T3 publication Critical patent/DK0483194T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Image Processing (AREA)
  • Closed-Circuit Television Systems (AREA)
  • Burglar Alarm Systems (AREA)
  • Alarm Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK90910699.9T 1989-07-18 1990-07-17 IgG3-antistoffer med forkortet hængselsregion og en komplementaktiveringstest DK0483194T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898916400A GB8916400D0 (en) 1989-07-18 1989-07-18 Modified igg3

Publications (1)

Publication Number Publication Date
DK0483194T3 true DK0483194T3 (da) 1996-05-13

Family

ID=10660201

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90910699.9T DK0483194T3 (da) 1989-07-18 1990-07-17 IgG3-antistoffer med forkortet hængselsregion og en komplementaktiveringstest

Country Status (8)

Country Link
US (1) US5348876A (da)
EP (1) EP0483194B1 (da)
JP (1) JPH05500303A (da)
AT (1) ATE136909T1 (da)
DE (1) DE69026615T2 (da)
DK (1) DK0483194T3 (da)
GB (1) GB8916400D0 (da)
WO (1) WO1991001335A1 (da)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6893636B2 (en) * 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US7033589B1 (en) 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
EP1746107B1 (en) 1998-04-02 2014-12-17 Genentech, Inc. Antibody variants and fragments thereof
AU778683B2 (en) * 1999-01-15 2004-12-16 Genentech Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6193892B1 (en) 1999-03-03 2001-02-27 Promega Corporation Magnetic separation assembly and method
IL151348A0 (en) 2000-04-13 2003-04-10 Univ Rockefeller Enhancement of antibody-mediated immune responses
FR2836146B1 (fr) * 2002-02-15 2005-01-07 Urrma R & D IMMUNOGLOBULINE IgG3 MARQUEUR DE PROTECTION CONTRE LES MALADIES VIRALES INFECTIEUSES ET SES UTILISATIONS
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8530627B2 (en) * 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) * 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8193318B2 (en) * 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) * 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8044180B2 (en) * 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
JP4033390B2 (ja) * 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 不死化ナチュラルキラー細胞株
CA2499300A1 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1587540B1 (en) 2003-01-09 2021-09-15 MacroGenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
CA2530388A1 (en) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
EP1663306A2 (en) * 2003-09-05 2006-06-07 Genentech, Inc. Antibodies with altered effector functions
CN100467488C (zh) 2003-12-30 2009-03-11 默克专利有限公司 Il-7融合蛋白
WO2005078442A1 (en) * 2004-02-10 2005-08-25 Dantini Daniel C Comprehensive food allergy test
US8309318B2 (en) * 2004-02-10 2012-11-13 Brendan Bioscience, Llc Detection of antigen specific immunocomplexes
WO2005110474A2 (en) 2004-05-10 2005-11-24 Macrogenics, Inc. HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
DK1776384T3 (da) 2004-08-04 2013-09-02 Mentrik Biotech Llc VARIANT-Fc-REGIONER
EP1778728A2 (en) * 2004-08-19 2007-05-02 Genentech, Inc. Polypeptide variants with altered effector function
JP2008511337A (ja) * 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
US7632497B2 (en) * 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
EP1674479A1 (en) * 2004-12-22 2006-06-28 Memorial Sloan-Kettering Cancer Center Modulation of Fc Gamma receptors for optimizing immunotherapy
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US9296816B2 (en) 2005-04-15 2016-03-29 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
PT2573114T (pt) * 2005-08-10 2016-07-13 Macrogenics Inc Identificação e manipulação de anticorpos com regiões fc variantes e métodos de utilização dos mesmos
AU2007226752A1 (en) * 2006-03-10 2007-09-20 Macrogenics, Inc. Identification and engineering of antibodies with variant heavy chains and methods of using same
GB2436616A (en) * 2006-03-29 2007-10-03 Inverness Medical Switzerland Assay device and method
ES2654040T3 (es) 2006-03-31 2018-02-12 Chugai Seiyaku Kabushiki Kaisha Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
ES2489646T3 (es) * 2006-05-26 2014-09-02 Macrogenics, Inc. Anticuerpos humanizados específicos a Fc gamma RIIB y sus métodos de uso
CA2656224C (en) * 2006-06-26 2018-01-09 Macrogenics, Inc. Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
HUE030269T2 (en) 2006-06-26 2017-04-28 Macrogenics Inc FC RIIB-specific antibodies and methods for their use
EP2047269B1 (en) * 2006-07-14 2014-04-30 Eötvös Lorand University Measurement of complement activation products on antigen microarrays
US20080112961A1 (en) * 2006-10-09 2008-05-15 Macrogenics, Inc. Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
PH12021552811A1 (en) 2007-09-26 2022-11-21 Chugai Seiyaku Kk Modified antibody constant region
BRPI0817294A2 (pt) 2007-09-26 2015-03-17 Chugai Pharmaceutical Co Ltd Método de modificação do ponto isoelétrico de anticorpo via substituição de aminoácido em cdr.
US8795667B2 (en) * 2007-12-19 2014-08-05 Macrogenics, Inc. Compositions for the prevention and treatment of smallpox
CN106349390B (zh) 2008-04-02 2019-12-10 宏观基因有限公司 Bcr-复合体-特异性抗体和其使用方法
EP2247304B1 (en) * 2008-04-02 2016-05-25 MacroGenics, Inc. Her2/neu-specific antibodies and methods of using same
US20110081347A1 (en) * 2008-06-04 2011-04-07 Macrogenics, Inc. Antibodies with Altered Binding to FcRn and Methods of Using Same
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
TWI646193B (zh) 2009-03-19 2019-01-01 中外製藥股份有限公司 抗體恆定區域改變體
US10150808B2 (en) * 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
HUE036549T2 (hu) 2009-10-07 2018-07-30 Macrogenics Inc A fukozilezés mértékének megváltozása miatt javított effektor funkciót mutató, Fc-régiót tartalmazó polipeptidek, valamint eljárások alkalmazásukra
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
SG183847A1 (en) 2010-03-04 2012-10-30 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
MX339622B (es) 2010-08-02 2016-06-02 Macrogenics Inc Diacuerpos covalentes y sus usos.
PT2691417T (pt) 2011-03-29 2018-10-31 Roche Glycart Ag Variantes de fc de anticorpos
KR102030531B1 (ko) 2011-05-21 2019-10-10 마크로제닉스, 인크. 탈면역화된 혈청-결합 도메인 및 혈청 반감기를 연장하기 위한 그것의 용도
ES2896493T3 (es) 2012-07-13 2022-02-24 Roche Glycart Ag Anticuerpos biespecíficos anti-VEGF/anti-ANG-2 y su uso en el tratamiento de enfermedades vasculares oculares
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
RU2020115527A (ru) 2013-03-14 2020-07-07 Макродженикс, Инк. Биспецифичные молекулы, иммунореактивные с иммунными эффекторными клетками, экспрессирующими активирующий рецептор
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
ES2881306T3 (es) 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Método para la producción de heteromultímeros de polipéptidos
JP6932639B2 (ja) 2014-09-29 2021-09-08 デューク ユニバーシティ Ｈｉｖ‐１エンベロープ標的化アームを備える二重特異性分子
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
CA3004288A1 (en) 2015-12-28 2017-07-06 Nobuyuki Tanaka Method for promoting efficiency of purification of fc region-containing polypeptide
BR112018071105A2 (pt) 2016-04-15 2019-02-26 Macrogenics, Inc. conjugado de droga e anticorpo, molécula de ligação, composição farmacêutica e uso

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2840847A1 (de) * 1978-09-20 1980-04-03 Behringwerke Ag Verfahren zum nachweis und zur bestimmung komplementbindender antikoerper
DE3883899T3 (de) * 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
FR2609398A1 (fr) * 1988-04-19 1988-07-15 Zagyansky Yuly Structure de l'igg plus antigene et complement, ses mecanismes et les consequences importantes
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
WO1989007142A1 (en) * 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies

Also Published As

Publication number Publication date
GB8916400D0 (en) 1989-09-06
JPH05500303A (ja) 1993-01-28
WO1991001335A1 (en) 1991-02-07
DE69026615D1 (de) 1996-05-23
ATE136909T1 (de) 1996-05-15
US5348876A (en) 1994-09-20
EP0483194A1 (en) 1992-05-06
EP0483194B1 (en) 1996-04-17
DE69026615T2 (de) 1996-09-26

Similar Documents

Publication Publication Date Title
DK0483194T3 (da) IgG3-antistoffer med forkortet hængselsregion og en komplementaktiveringstest
ES2119369T3 (es) Dispositivo sensor para un ensayo sandwich.
DE3852996D1 (de) Immunoassayverfahren zum Nachweis von Antigenen.
DE3779704D1 (de) Verfahren und testkit zur bestimmung freier wirkstoffe in biologischen fluessigkeiten.
ES512498A0 (es) "metodo y su correspondiente aparato para el ensayo de anticuerpos con respecto a antigenos solubles".
DK0564494T3 (da) Testmetode og reagenssæt dertil
PT97839A (pt) Processo para a deteccao e/ou doseamento de hormonas e anticorpos utilizaveis no referido processo de deteccao
DK0755517T3 (da) Fremgangsmåde til detektion af tilstedeværelse af en Mycobacterium-art og et kit og antistoffer til anvendelse i denne
ATE188551T1 (de) Feststellung von antikörperproduktion
ATE286596T1 (de) Chemische modifikation von antikörpern und antigenen
DK608789D0 (da) Cea-immunanalyse uden falske positive foraarsaget af humant anti-museantistof
ATE323284T1 (de) Assay zur identifikation von ige-antikörper- suppressoren
ITMI930477A1 (it) Saggio per la determinazione di un antigene/anticorpo in un campione di prova e corredo per l'attuazione del saggio
DE3863270D1 (de) Immuntest.
FI943921A (fi) Vapaan trypsinogeeni-2:n määritys